Interventional Recruiting Phase 2
NCT06112522 on ClinicalTrials.gov
Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
Official title: Open, Prospective Study Evaluating the Efficacy and Safety of 0.05% Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
- Sponsor: Centre Hospitalier Universitaire de Nice
- Enrollment: 50 (Estimated)
- Study start: 2024-02-16 (Actual)
- Primary completion: 2027-12-16 (Estimated)
- Study completion: 2027-12-16 (Estimated)
- Allocation: N/a
- InterventionModel: Single Group
- InterventionModelDescription: Single-Arm, Open-Label, Single Center
- Masking: None
- PrimaryPurpose: Treatment
Brief Summary
his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp
Conditions
- Cell Carcinoma
Intervention / Treatment
- Drug: Tirbanibulin
Primary Outcome Measures
-
Incidence of Treatment-Emergent Adverse Events
(up to 17 months)
IMC
Countries
France
Locations and Investigators
-
CHU de Nice - Hôpital de l'Archet, Nice, France (Recruiting)
- Philippe Bahadoran, PhD
- Philippe Bahadoran (Principal Investigator)
Study Officials
- philippe Bahadoran, PhD (Principal Investigator) — CHU de Nice, Service de Dermatologie